Adaptimmune Is A Good Speculative Biotech, But More Confirmation Is Needed From Next Study [Seeking Alpha]
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: Seeking Alpha
Adaptimmune Is A Good Speculative Biotech, But More Confirmation Is Needed From Next Study Summary Adaptimmune has been able to achieve partial responses and stable disease in patients with synovial sarcoma in a phase 1 study using ADP-A2M4. A phase 2 study using ADP-A2M4 for the treatment of patients with synovial sarcoma and myxoid/round cell liposarcoma is underway, pending positive data product could possibly be commercialized by 2022. Adaptimmune has established supply and manufacturing agreement with Cryoport Inc., so that product can be accounted for and shipped to hospitals accordingly if and once ADP-A2M4 is approved for commercialization. The company has $34.6 million in cash as of June 30, 2019 and it believes it has enough cash to fund its operations through Q3 of 2020. Adaptimmune Therapeutics ADAP announced some preliminary positive data in patients with synovial sarcoma Preliminary Data Shows A Good Amount of Responses To Therapy Adaptimmune reported data at the 2019 Eu
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 [Yahoo! Finance]Yahoo! Finance
- Global CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & Phase [Yahoo! Finance]Yahoo! Finance
- Adaptimmune: Huge Opportunity Amid Their Setback With Genentech [Seeking Alpha]Seeking Alpha
- Garry Menzel joins GHO Capital as Operating Partner [Yahoo! Finance]Yahoo! Finance
- Adaptimmune (ADAP) Down on End of Collaboration With Roche [Yahoo! Finance]Yahoo! Finance
ADAP
Sec Filings
- 4/22/24 - Form ARS
- 4/12/24 - Form 8-K
- 4/11/24 - Form DEF
- ADAP's page on the SEC website